A comment on Craig et al.: ''Retigabine for the adjunctive treatment of adults with partial-onset seizures in epilepsy with and without secondary generalization: a NICE single technology appraisal''.

Pharmacoeconomics · 2013 · PMC3671124 · PMID 23539279

Europe PMC DOI

hedged sentence

0.0001

closest p · 0.0× alpha

0.0001

boldest claim

The sentences

highly significantp < 0.0001actually significant

Likewise we found a highly significant dose-dependent effect across all treatments for the rate of adverse events leading to discontinuation ( p < 0.0001), yet a nonsignificant (retigabine, lacosamide) or small (eslicarbazepine; p = 0.0276) impact of dose variation on the rate of seizure freedom (most likely due to limitations of rare event analysis).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.